Your session is about to expire
← Back to Search
This trial will test the efficacy and safety of ALXN2050 in people with gMG.
- Myasthenia Gravis
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Find a Location
Who is running the clinical trial?
- You have a positive blood test for anti-AChR antibodies.You must have a certain level of difficulty with daily activities, like moving around and taking care of yourself, to be in the study.Your kidney function is very low, measured by a test called estimated glomerular filtration rate (eGFR).You are showing signs of getting sicker when you are screened for the trial or at any time before starting the trial.You have a positive blood test for anti AChR antibodies, which confirms you have myasthenia gravis.You have received intravenous or subcutaneous immunoglobulin within the past 4 weeks.You have a thymic malignancy, carcinoma, or thymoma that has not been treated yet. If it has been treated before, you may still be eligible if you meet certain conditions outlined in the study protocol.You have been diagnosed with myasthenia gravis using specific tests that show problems with nerve and muscle communication.You have been diagnosed with myasthenia gravis based on a positive response to a specific test using a medication called edrophonium chloride.You have taken tacrolimus or cyclosporine in the past 4 weeks.Your signs or symptoms of myasthenia gravis improved while taking a specific oral medication, as decided by your doctor.You have been diagnosed with Myasthenia Gravis and are classified as Class II to IV by the Myasthenia Gravis Foundation of America.Your MG-ADL total score must be at least 5, with at least half of the score coming from non-eye-related symptoms, at the Screening Visit and on the first day of the study.It seems like there might be a typo or incomplete information. Could you please provide more context or clarify the criterion you're referring to?You have been diagnosed with Myasthenia Gravis and are classified as Class II to IV by the Myasthenia Gravis Foundation of America.If you are taking certain medications that weaken your immune system, like immunosuppressive therapies or corticosteroids, you must have been on a stable dose for some time and not expect any changes to your medication during the study.You have abnormal nerve and muscle function, or you had a positive response to a specific test for myasthenia gravis, or your signs and symptoms improved with a certain type of medication, as determined by your doctor.
- Group 1: ALXN2050: 180 mg
- Group 2: ALXN2050: 120 mg
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there extensive implementation of this experiment in the US?
"Currently, 21 trial sites are recruiting patients. These centers span from San Francisco to Nashville and Phoenix with other locations between them. To reduce any potential travel burden, it is suggested that participants select the clinic nearest them for enrolment."
Has ALXN2050 been given regulatory clearance by the FDA?
"Due to the fact that ALXN2050 is in Phase 2, there is some supporting evidence for safety but none backing its efficacy. Thus, our team assigned it a score of two on the 1-3 scale."
Are there still opportunities for participants to join this clinical trial?
"As displayed on clinicaltrials.gov, this medical research is now in the recruitment phase having first been posted on December 30th 2021 and recently updated November 11th 2022."
How many participants are contributing to this research endeavor?
"Affirmative. Clinicaltrials.gov offers proof that this trial, which was initially registered on December 30th 2021, is actively searching for participants. About 70 patients are needed from 21 distinct sites."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends